Diagen signs new distribution agreement with SpeeDx
Oct 24 2017 Read 527 Times
Sydney, Australia-based SpeeDx has announced a distribution agreement with Scandinavian clinical laboratory supplier Diagen to supply its polymerae chain reaction product lines to hospitals and research facilities across Sweden, Norway and Denmark.
The PlexPCR® range will allow Diagen’s customers to obtain complex diagnostic information on sexually transmitted infections or other infectious diseases from a single, cost-effective test. The agreement will also give them access to the ResistancePlus MG assay. This is the first CE-IVD test to simultaneously detect Mycoplasma genitalium and genetic markers for azithromycin resistance, as recommended by the new European guidelines on M. genitalium resistance screening in the management of non-gonococcal urethritis.
“Scandinavia is home to some important thought leaders influencing sexual health and STI testing practices across Europe,” said Colin Denver, CEO of SpeeDx. “We see our partnership with Diagen as key to offering the best service to laboratories across these important markets.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Choosing the Optimum Plasma Spectrochemistry Technique for Measuring Elemental Impurities in Pharmaceuticals - Monitoring Airborne Molecular Contamination in Indoo...
View all digital editions
Jun 19 2018 Santiago de Compostela, Spain
Jun 20 2018 Cologne, Germany
Jun 27 2018 Tokyo, Japan
Jul 08 2018 Baltimore, MD, USA
Jul 29 2018 Chicago, IL, USA